Loading cancer entity…
Loading cancer entity…
Clinical trials
10,627 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,641)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03033914 | A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) | active not recruiting | Phase 1 / Phase 2 | 82 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Feb 17, 2026 | clinicaltrials |
| NCT05391750 | Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma | active not recruiting | Phase 1 | 7 | Emory UniversityOTHER | 1 | Feb 17, 2026 |
| NCT05551936 | A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma | active not recruiting | Phase 1 / Phase 2 | 42 | Vaishalee KenkreOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04690595 | BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL | active not recruiting | Phase 1 | 24 | PeproMene Bio, Inc.INDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06939283 | A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma | active not recruiting | Phase 1 / Phase 2 | 100 | Werewolf Therapeutics, Inc.INDUSTRY | 1 | Feb 10, 2026 | clinicaltrials |
| NCT01192464 | EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma(CARCD30) | active not recruiting | Phase 1 | 18 | Baylor College of MedicineOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03933735 | A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 220 | AbbVieINDUSTRY | 2 | Feb 6, 2026 | clinicaltrials |
| NCT04323956 | Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma | active not recruiting | Phase 1 | 50 | Mayo ClinicOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT03842696 | Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation | active not recruiting | Phase 1 / Phase 2 | 43 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT05071209 | Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 2 | Jan 23, 2026 | clinicaltrials |
| NCT04586426 | A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma(RedirecTT-1) | active not recruiting | Phase 1 / Phase 2 | 228 | Janssen Research & Development, LLCINDUSTRY | 7 | Jan 16, 2026 | clinicaltrials |
| NCT05222555 | Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients(MINDway) | active not recruiting | Phase 1 / Phase 2 | 53 | Incyte CorporationINDUSTRY | 9 | Jan 16, 2026 | clinicaltrials |
| NCT05737628 | First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228 | active not recruiting | Phase 1 | 17 | Byondis B.V.INDUSTRY | 4 | Jan 16, 2026 | clinicaltrials |
| NCT03278782 | Study of Pembrolizumab (MK-3475) in Combination With Romidepsin | active not recruiting | Phase 1 / Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05211336 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System | active not recruiting | Phase 1 | 14 | National Cancer Institute (NCI)NIH | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05464329 | Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma | active not recruiting | Phase 1 | 24 | Washington University School of MedicineOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT04572763 | Copanlisib Plus Venetoclax in R/R DLBCL | active not recruiting | Phase 1 / Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04843904 | Safe Accelerated Venetoclax Escalation in CLL(SAVE) | active not recruiting | Phase 1 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05775094 | A Study of Romosozumab in Women With Multiple Myeloma and Osteoporosis | active not recruiting | Phase 1 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT03330691 | A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia | active not recruiting | Phase 1 | 78 | Seattle Children's HospitalOTHER | 2 | Dec 15, 2025 | clinicaltrials |
| NCT02932280 | Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment | active not recruiting | Phase 1 / Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Dec 5, 2025 | clinicaltrials |
| NCT04184050 | Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) | active not recruiting | Phase 1 | 100 | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 3 | Dec 5, 2025 | clinicaltrials |
| NCT03352765 | A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients | active not recruiting | Phase 1 | 28 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT04787263 | CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML | active not recruiting | Phase 1 / Phase 2 | 32 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT04091126 | Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma(DREAMM 9) | active not recruiting | Phase 1 | 118 | GlaxoSmithKlineINDUSTRY | 10 | Nov 28, 2025 | clinicaltrials |
| NCT06285422 | Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) | active not recruiting | Phase 1 | 6 | Sana BiotechnologyINDUSTRY | 1 | Nov 28, 2025 | clinicaltrials |
| NCT02050347 | Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)(CARPASCIO) | active not recruiting | Phase 1 | 7 | Baylor College of MedicineOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT02337985 | Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 10 | City of Hope Medical CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT02979522 | A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 59 | TakedaINDUSTRY | 4 | Nov 10, 2025 | clinicaltrials |
| NCT04684563 | huCART19-IL18 in CD19+ Cancers | active not recruiting | Phase 1 | 72 | University of PennsylvaniaOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05081479 | A Study of N-Acetylcysteine (N-AC) in People Receiving CAR T-cell Therapy for Lymphoma | active not recruiting | Phase 1 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT05574114 | A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma | active not recruiting | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT00368082 | Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)(TGF-beta) | active not recruiting | Phase 1 | 8 | Baylor College of MedicineOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT00881920 | Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL(CHARKALL) | active not recruiting | Phase 1 | 54 | Baylor College of MedicineOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT05565417 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | active not recruiting | Phase 1 / Phase 2 | 67 | Immunitas TherapeuticsINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT01697930 | A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R) | active not recruiting | Phase 1 | 67 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT02909036 | Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. | active not recruiting | Phase 1 | 46 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT05270057 | Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies(LONCA) | active not recruiting | Phase 1 | 11 | Medical College of WisconsinOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT02153580 | Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia | active not recruiting | Phase 1 | 37 | City of Hope Medical CenterOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT05878184 | Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) | active not recruiting | Phase 1 | 16 | Sana BiotechnologyINDUSTRY | 2 | Oct 2, 2025 | clinicaltrials |
| NCT03147885 | Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 43 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT04606433 | Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 | 47 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05192486 | A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL) | active not recruiting | Phase 1 / Phase 2 | 12 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05485753 | A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) | active not recruiting | Phase 1 / Phase 2 | 7 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05627856 | A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL | active not recruiting | Phase 1 / Phase 2 | 4 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT04446962 | LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)(LOC-R01) | active not recruiting | Phase 1 / Phase 2 | 118 | Institut CurieOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05621096 | Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 33 | University of NebraskaOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05823571 | Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients | active not recruiting | Phase 1 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06381141 | A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma | active not recruiting | Phase 1 | 30 | Cullinan Therapeutics Inc.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 17, 2026source: clinicaltrials